Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam

European Urology

Volumn 59, Issue 4, 2011, Pages 498-505

  Bul, Meelan ^a   Van Leeuwen, Pim J ^a   Zhu, Xiaoye ^a   Schröder, Fritz H ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Early detection of cancer; Incidence; Prostate specific antigen; Prostatic neoplasms; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; BIOPSY; COMORBIDITY; EARLY DIAGNOSIS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; NETHERLANDS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952282237     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.01.001     Document Type: Article

References (23)

1. M.C. Wang, L.A. Valenzuela, G.P. Murphy, and T.M. Chu Purification of a human prostate specific antigen Invest Urol 17 1979 159 163 (Pubitemid 10132507)
2. T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, and E. Redwine Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate N Engl J Med 317 1987 909 916 (Pubitemid 17147932)
3. W.J. Catalona, D.S. Smith, and T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
4. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 2010 765 781
5. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M.J. Thun Cancer statistics, 2009 CA Cancer J Clin 59 2009 225 249
6. F.H. Schröder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
7. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
8. M.J. Roobol, M. Kerkhof, and F.H. Schröder Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC) Eur Urol 56 2009 584 591
9. I.M. Thompson, D.P. Ankerst, and C. Chi Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower JAMA 294 2005 66 70 (Pubitemid 41002840)
10. H.J. De Koning, J. Blom, and J.W. Merkelbach Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 Suppl 2 2003 71 78 (Pubitemid 38091145)
11. M.J. Roobol, W.J. Kirkels, and F.H. Schröder Features and preliminary results of the Dutch Centre of the ERSPC (Rotterdam, The Netherlands) BJU Int 92 Suppl 2 2003 48 54 (Pubitemid 38091140)
12. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
13. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
14. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436 (Pubitemid 350002992)
15. P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
16. M.J. Roobol, A. Grenabo, F.H. Schröder, and J. Hugosson Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam J Natl Cancer Inst 99 2007 1296 1303 (Pubitemid 47398681)
17. L.H. Kuller, A. Thomas, G. Grandits, J.D. Neaton Multiple Risk Factor Intervention Trial Research Group Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer Cancer Epidemiol Biomarkers Prev 13 2004 373 377 (Pubitemid 38737461)
18. D. Connolly, A. Black, A. Gavin, P.F. Keane, and L.J. Murray Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation Cancer Epidemiol Biomarkers Prev 17 2008 271 278 (Pubitemid 351272775)
19. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
20. M.J. Roobol, D.W. Roobol, and F.H. Schröder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346 (Pubitemid 40248025)
21. P.J. van Leeuwen, D. Connolly, and T.L. Tammela Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865
22. M.J. Roobol, E.W. Steyerberg, and R. Kranse A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer Eur Urol 57 2010 79 85
23. S. Perdon, V. Cavadas, and G. Di Lorenzo Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT Calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3 Eur Urol 59 2011 81 87